<DOC>
	<DOCNO>NCT01532856</DOCNO>
	<brief_summary>This protocol international , multicenter , comparative , open randomize study design compare safety efficacy ( term response rate ) three induction chemotherapy scheme -Thalidomide/Cyclophosphamide/Dexamethasone versus Thalidomide/Dexamethasone versus Thalidomide/Melphalan/Prednisone . Finally , study also design compare safety efficacy ( term duration response ) two maintenance chemotherapy regimens - Thalidomide/Prednisone versus Thalidomide . Each treatment arm include 100 patient assessment schedule visit conduct three period : Pre-treatment , treatment monitoring . Security evaluate monitor adverse event , physical examination , vital sign biochemical study . Response treatment evaluate accord EBMT21 criterion assess day 1 cycle induction , end nine cycle induction therapy monthly first year maintenance therapy every 3 month thereafter .</brief_summary>
	<brief_title>Iberoamerican Protocol With Thalidomide Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>&gt; 65 year old non candidate autologous stem cell transplant Patient must newly diagnose Multiple Myeloma accord establish criterion symptom . Steroid pulse administration allow required emergency prior start induction therapy bisphosphonates administration Patient must measurable disease , define follow : secretory multiple myeloma , measurable disease define presence measurable monoclonal component serum urine excretion light chain great equal 200 mg/24 hour ( Annex 5 ) Measured ECOG &lt; 2 state level . The patient must life expectancy great 3 month . Adequate laboratory value prior induction treatment initiation , define follow : 1 . Platelet count ≥ 50000/mm3 , hemoglobin ≥ 8 g / dl absolute neutrophil count ≥ 1000/mm3 . Lower value permit due BM infiltration . 2 . Corrected serum calcium ≤ 14mg/dl . 3 . Aspartate transaminase ( AST ) : ≤ 2.5 x normal upper limit . 4 . Alanine transaminase ( ALT ) : ) : ≤ 2.5 x normal upper limit . 5 . Total bilirubin : ≤ 1.5 x normal upper limit . 6 . Serum creatinine ≤ 2 mg / dl . Men ( include vasectomy do ) must use barrier contraception ( latex condom ) sex woman potential childbearing , least four week thalidomide last dose . Nonsecretory MM . Previous treatment multiple myeloma exception steroid pulse emergency require treatment begin induction , administration bisphosphonates radiation therapy . Basal peripheral neuropathy high grade 2 within 14 day inclusion . Known thalidomide hypersensitivity . Use investigational agent within 30 day prior inclusion . Known human immunodeficiency virus ( HIV ) infection , detectable surface antigen hepatitis B active infection hepatitis C viruses Myocardial infarction within 6 month prior inclusion heart functional class III IV accord New York Heart Association ( NYHA ) heart failure , angina , uncontrolled ventricular arrhythmia acute ischemia detect electrocardiogram conduction system abnormality . Participation another clinical trial receive investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>thalidomide</keyword>
	<keyword>comparative</keyword>
	<keyword>elderly</keyword>
</DOC>